Overview

NeuroXess is one of China’s leading implantable BCI companies, having completed the country’s first prospective invasive brain-computer interface human trial in 2025. The company is now building what it calls China’s first dedicated BCI production facility, signalling a shift from lab-bench prototyping to scale manufacturing.

Technology

NeuroXess develops polyimide mesh electrodes — a non-penetrating design that conforms to the brain’s surface without piercing cortical tissue. The implant is fully integrated with an internal battery, eliminating external power requirements. The company has demonstrated a data transmission rate of 5.2 bits per second and accumulated significant human implant experience.

Manufacturing

NeuroXess maintains its corporate and research headquarters in Shanghai, but the 14,300-square-metre production facility broke ground in March 2026 in Jiangxi province rather than Shanghai. The “super factory” is designed to deliver tens of thousands of implantable units and surgical robots, and represents a significant step toward mass manufacturing of implantable neural interfaces in China. The Shanghai-HQ / Jiangxi-manufacturing split mirrors a common Chinese deeptech footprint where R&D anchors in a tier-1 city while volume production scales in a province with lower land and labour costs.

Competitive Position

NeuroXess is positioned as a direct global competitor to Neuralink and other Western BCI companies, leveraging government support, lower development costs, and a rapidly maturing regulatory environment to accelerate commercial timelines. Co-founder Phoenix Peng departed in 2025 to launch Gestala, an ultrasound-focused BCI startup.